A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness
Public ClinicalTrials.gov record NCT00666575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Actual Use Study of the Safety and Tolerability of Gabapentin 500 mg in a Potential OTC Population
Study identification
- NCT ID
- NCT00666575
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 2,105 participants
Conditions and interventions
Conditions
Interventions
- Gabapentin Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2004
- Primary completion
- Not listed
- Completion
- Apr 30, 2005
- Last update posted
- Feb 1, 2021
2004 – 2005
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36608 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85018 | — |
| Pfizer Investigational Site | Beverly Hills | California | 90211 | — |
| Pfizer Investigational Site | San Francisco | California | 94102 | — |
| Pfizer Investigational Site | Clearwater | Florida | 33765 | — |
| Pfizer Investigational Site | DeLand | Florida | 32720 | — |
| Pfizer Investigational Site | New Port Richey | Florida | 34652 | — |
| Pfizer Investigational Site | Pembroke Pines | Florida | 33024 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33409 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30328 | — |
| Pfizer Investigational Site | Boise | Idaho | 83704 | — |
| Pfizer Investigational Site | Boise | Idaho | 83712 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46250 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89104 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89128 | — |
| Pfizer Investigational Site | Santa Fe | New Mexico | 87505 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Austin | Texas | 78705 | — |
| Pfizer Investigational Site | Fort Worth | Texas | 76135 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78205 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84102 | — |
| Pfizer Investigational Site | West Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00666575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2021 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00666575 live on ClinicalTrials.gov.